Clinical Trials Browser

Terminated × Interventional × Fenretinide × Clear all

NCT01187810 2022-03-31

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01553071 2022-03-31

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

Phase 1 Terminated

Neoplasms, Recurrence

NCT02163356 2022-03-31

SPOC2013-001

Phase 1 Terminated

Neuroblastoma, Recurrence

NCT01535157 2020-08-27

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Phase 1/2 Terminated

Ovarian Neoplasms

NCT00102635 2018-11-15

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1 Terminated

Head and Neck Neoplasms

NCT01479192 2018-11-07

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Phase 3 Terminated

Neoplasms

NCT00288067 2014-10-06

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Terminated

32 enrolled 7 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00003223 2012-07-24

SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

Phase 2 Terminated

Head and Neck Neoplasms, Mouth Neoplasms